产品展示

Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (ab92547) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P, WB and mIHC.

Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (ab92547) was first used in a scientific publication in 1976 and has been cited over 1733 times in peer reviewed journals. It's performance in IHC, Western Blot and immunofluorescence in human and mouse samples is trusted by the scientific community.

Abcam's high quality manufacturing and validation processes ensure Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (ab92547) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.

The specificity of Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (ab92547) has been confirmed by Western Blot testing in Vimentin knockout A549 cells (ab288984).

Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (ab92547) has 91 independent reviews from customers.

Vimentin antibodies are often used as loading controls in Western Blot. Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker has been verified in Western Blot samples and detects a band at 54kDa Molecular weight.

Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (ab92547) specifically detects Vimentin (UniProt ID: P08670; Molecular weight: 54kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL).

Conjugation-ready, carrier free format available for antibody clone EPR3776 - ab193555.

Antibody clone EPR3776 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 594, Alexa Fluor® 488, HRP, Alexa Fluor® 647, Alexa Fluor® 568, Alexa Fluor® 555, PE, Alexa Fluor® 405, APC, Alexa Fluor® 750 (ab154207, ab185030, ab194718, ab194719, ab202504, ab203428, ab209446, ab210152, ab314250, ab321763).

Vimentin is a protein that supports the structural integrity of cells and is often upregulated in cancer cells, contributing to their aggressive behaviour. It plays a role in cancer progression and metastasis, helping tumors evade the immune system.

Patented technologyOur RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?This product is a recombinant monoclonal antibody, which offers several advantages including:

• - High batch-to-batch consistency and reproducibility
• - Improved sensitivity and specificity
• - Long-term security of supply
• - Animal-free batch production